United Therapeutics Corporation

NASDAQ:UTHR

Biotechnology

Healthcare
$577.34 -3.27%

-$18.01 today

Market cap
$24.59B
Beta
0.57
P/E (TTM)
18.0
EPS (TTM)
$29.60
52W Low $272.12High $609.35

Volume 0.42M

Average 0.52M

UTHR Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

United Therapeutics CorporationNASDAQ: UTHR

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash turns positive

Q2 FY2026 net change in cash was $729M, compared with -$306.8M a year earlier. Trailing-twelve-month net change in cash was $210.1M.

Context

  • Net change in cash amounted to 4.4% of revenue in FY2025, down 12.6 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near $729M or moves back toward the trailing-twelve-month quarterly average of $52.53M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$729M+251.0% QoQ
Last fiscal yearDec 2025
-$140.1M-128.6% YoY
LTMJun 2026
$210.1M-11.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+337.6%——
1 year-128.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(140.1M) USD
Year-over-year change
-128.6%

Net Change in Cash vs competitors

How UTHR compares with its peers on the latest reported figures

  • UTHR's LTM Jun 2026 net change in cash of $210.1M is the 2nd largest of the 5 companies compared; the peer median is $5.63M.
  • Its year-over-year change of -11.5% is the 2nd highest of 5, against a peer median of -108.3%.
  • Net change in cash amounts to 6.7% of revenue for UTHR, versus a peer median of 21.4%.
UTHR Competitors Peer median
Net Change in Cash for UTHR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INSMInsmed IncorporatedLTM Jun 2026$739.56M -2070.8%—65.0%
UTHRUnited Therapeutics CorporationLTM Jun 2026$210.1M -11.5%—6.7%
LQDALiquidia CorporationLTM Jun 2026$96.36M +119.8%-26.5%21.4%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$23.87M -133.6%——
TVTXTravere Therapeutics, Inc.LTM Sep 2026$12.61M -83.1%—1.9%
Peer median (excluding UTHR) $5.63M-108.3%-26.5%21.4%

Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income475.8M727.3M984.8M1.2B1.33B
Depreciation & Amortization49.9M51.3M53.2M72.5M85.6M
Deferred Income Tax000097.7M
Stock-Based Compensation138.5M106.8M39.1M144M147.7M
Change in Working Capital(174.2M)(141.2M)(97.8M)(60.2M)(106.4M)
Accounts Receivables(41.3M)(21.7M)(58.5M)(400K)(70.9M)
Inventory(7.5M)(13.4M)(13.6M)(46.9M)(52.6M)
Accounts Payables000097.9M
Other Working Capital(125.4M)(106.1M)(25.7M)(12.9M)(80.9M)
Other Non-Cash Items108.2M58.3M(1.3M)(24.3M)2M
Operating Cash Flow598.2M802.5M978M1.33B1.56B
Capital Expenditures(120.8M)(138.8M)(230.4M)(246.5M)(520.5M)
Acquisitions (Net)0(1.5M)(89.2M)(30.5M)0
Purchases of Investments(1.9B)(1.71B)(2.51B)(1.65B)(3.46B)
Sales of Investments1.53B1.03B2.14B2.37B1.58B
Other Investing Activities03.5M(23M)(28.5M)1.85B
Investing Cash Flow(486.9M)(811.5M)(719.6M)417.2M(551.3M)
Debt Repayment00(100M)(400M)(300M)
Common Stock Issued0000183.1M
Common Stock Repurchased(10.8M)(11.4M)(13.8M)(1.01B)(1B)
Dividends Paid00000
Other Financing Activities55.6M86.8M101.9M157.4M(33.1M)
Financing Cash Flow44.8M75.4M(11.9M)(1.25B)(1.15B)
Effect of Forex Changes00000
Net Change in Cash156.1M66.4M246.5M489.5M(140.1M)
Free Cash Flow477.4M663.7M747.6M1.08B1.04B

United Therapeutics Corporation

NASDAQ:UTHR

Intrinsic Alpha fair value

Locked

Current Price

$577.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.